Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-Mg 6-Month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring
Hormone Research in Paediatrics · 2024
DOI: 10.1159/000539020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hormone Research in Paediatrics, 2024. Verfasst von Lawrence A Silverman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Endocrinology, Goryeb Children's Hospital, Morristown, New Jersey, USA. Hauptthemen laut MEDLINE: Puberty, Precocious, Leuprolide, Gonadotropin-Releasing Hormone. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Studies of gonadotropin-releasing hormone analogues (intramuscular [IM] leuprolide acetate [LA] and triptorelin) for treatment monitoring of central precocious puberty (CPP) demonstrate this approach is effective for confirming pubertal hormone suppression. Herein, we provide new data using subcutaneous LA (SC LA), suggesting similar efficacy for treatment monitoring.
Methods
PubMed, Embase, and CINAHL were searched for studies of GnRHa used to monitor treatment of CPP. The titles and the abstracts were reviewed; 5 studies were selected. Additionally, new unpublished data for SC LA from the original phase 3 trial (primary data published by Klein et al.) were evaluated. Serum luteinizing hormone (LH) and leuprolide levels at screening, 1, 4, and 6 h after the first dose SC LA were analyzed and plotted.
Results
Data from 162 children (155 girls) were evaluated. SC and IM LA produced overlapping median LH concentration curves and peak LH concentrations after the first dose. For IM LA, subsequent doses yielded suppressed peak LH levels (2.7 IU/L [mean]). For SC LA, subsequent doses also resulted in significant suppressed peak LH levels (0.2 ± 0.02 IU/L) and achieved sex-steroid hormone suppression of >98%.
Conclusions
Compared to IM LA and triptorelin, long-acting SC LA shows similar burst kinetics and rapid LH rise after the first dose, followed by similar suppression of LH and sex steroids after subsequent doses. Since IM LA and triptorelin have demonstrated usefulness that is comparable to that of traditional GnRH stimulation testing for monitoring CPP, we presume that SC LA may be similarly employed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Endocrinology, Goryeb Children's Hospital, Morristown, New Jersey, USA.
- Center for Endocrinology, Diabetes, and Metabolism, and The Saban Research Institute at Children's Hospital Los Angeles, Los Angeles, California, USA.
- Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
- Nemours Children's Health, Jacksonville, United States and Assistant Professor of Pediatrics, Mayo College of Medicine, Jacksonville, Florida, USA.
Zitieren
APA
Silverman, L. A., Geffner, M. E., & Benson, M. (2024). Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-Mg 6-Month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring. Hormone Research in Paediatrics. https://doi.org/10.1159/000539020
Vancouver
Silverman LA, Geffner ME, Benson M. Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-Mg 6-Month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring. Hormone Research in Paediatrics. 2024. doi:10.1159/000539020
BibTeX
@article{Silverman2024,
author = {Silverman, Lawrence A and Geffner, Mitchell E and Benson, Matthew},
title = {Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-Mg 6-Month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring},
journal = {Hormone Research in Paediatrics},
year = {2024},
doi = {10.1159/000539020}
}
EUVIMED